Oncology for the Inquisitive Mind

In this episode, Michael and Josh continue to unpick the thorny question of germ-cell tumours, focusing this week on more advanced and relapsed disease. Germ cell tumours have an excellent prognosis,…

This episode is the first of a two-part mini-series where Michael and Josh attempt to untangle the complex topic of germ cell tumours, an area that requires specialist experience and a high-volume mu…

In this episode, Josh and Michael take a trip down a road less travelled by both patients and researchers, and examine the evidence (or lack thereof) of non-clear cell renal cell cancer, a less commo…

How do you increase access to phase 1 trials for a state with a population of 8 million people spread across 800,000 km^2? You collaborate! In this context, we explore NECTA. The New South Wales Earl…

Unlike the adjuvant space, treatment of advanced clear cell renal cell cancer has been a success story potentially only surpassed by advanced melanoma. What was once a horrific and quickly fatal dise…

Continuing on their Back to Basics GU extravaganza, Josh and Michael progress to the subject of kidney cancer, and bring you the answer to a question long unanswered: is there any benefit of adjuvant…

Josh and Michael return to their normal scheduled broadcast, continuing their never-ending Back to Basics series. In this episode, they discuss several interesting developments in the adjuvant manage…

In our final ASCO 2025 episode, Michael is joined by Prof Jeanne Tie, colorecal cancer lead at Peter MacCallum Cancer Centre to discuss some of the many highlights in colorectal and anal cancer. Star…

In this episode, Michael goes it alone, welcoming an old friend of the show, Dr Belinda Yeo, to discuss highlights in early breast cancer from ASCO 2025. The pair discuss an exciting new medication t…

Today, hosts Michael and Josh are joined by the wonderful Dr James McCracken to discuss highlights from ASCO 2025 in the areas of upper GI and hepatobiliary cancer. This episode focuses on two items …

Today, we discuss the latest advancements in gynecological oncology presented at ASCO 2025, featuring insights from Dr. Prachi Bhave. The conversation covers significant trials including the TRUST tr…

In this episode, Dr. Janet Abrahm shares transformative insights from ASCO 2025, focusing on palliative care and supportive care in oncology. Topics discussed include the role of exercise in cancer s…

In this episode, Dr. Ned McNamee discusses the latest advancements in lung cancer treatment presented at ASCO 2025, focusing on significant studies such as the Phase 3 DeLLphi-304 study and Checkmate…

Today, we cover ASCO 2025 in the genitourinary space, specifically bladder and renal cancer. Dr. Enrique Grande, a renowned oncologist and Program and Clinical Research lead of MD Anderson Cancer Cen…

Today, we’re joined by Professor Anthony Joshua, head of Medical Oncology at St. Vincent’s Hospital, Sydney, and a global leader in prostate cancer and melanoma.

In this episode, Professor Joshua dis…

In this episode, we unpack game-changing insights from ASCO 2025 with a spotlight on breast cancer. Joining us is Dr. Adam Brufsky, a trailblazing oncologist and professor at the University of Pittsb…

In our second plenary episode, we're spotlighting two pivotal phase 3 trials: SERENA-6, which explores ctDNA-guided treatment with camizestrant to delay progression in HR-positive, HER2-negative adva…

This year, Michael and Josh bring you the American Society of Clinical Oncology (ASCO) 2025. To keep it fresh, we're doing things a little differently, but rest assured, we'll bring along a global ho…

This week, we talk about metastatic bladder cancer. The last two years have seen drastic changes in this space, with the addition of immunotherapy and ADCs in a first-line setting. While exceptionall…

This week, we explore muscle-invasive bladder cancer (MIBC). This space has made significant progress with the completion of two pivotal trials. The first was VESPER, comparing two chemotherapy regim…